A revolution in molecular technology is leading to the discovery of many biomarkers of disease. Monitoring these biomarkers in a population may lead to earlier disease detection, and may prevent death from diseases like cancer that are more curable if found early. For markers whose concentration is associated with disease progression the earliest detection is achieved by monitoring the marker with an algorithm able to detect very small changes. One strategy is to monitor the biomarkers using a longitudinal algorithm that incorporates a subject's screening history into screening decisions. Longitudinal algorithms that have been proposed thus far rely on modeling the behavior of a biomarker from the moment of disease onset until its clinical presentation. Because the data needed to observe the early pre-clinical behavior of the biomarker may take years to accumulate, those algorithms are not appropriate for timely development using new biomarker discoveries. This manuscript presents a computationally simple longitudinal screening algorithm that can be implemented with data that is obtainable in a short period of time. For biomarkers meeting only a few modest assumptions our algorithm uniformly improves the sensitivity compared with simpler screening algorithms but maintains the same specificity. It is unclear what performance advantage more complex methods may have compared with our method, especially when there is doubt about the correct model for describing the behavior of the biomarker early in the disease process. Our method was specifically developed for use in screening for cancer with a new biomarker, but it is appropriate whenever the pre-clinical behavior of the disease and/or biomarker is uncertain.
INTRODUCTION
A revolution in molecular technology is leading the discovery of a large number of genes that are highly expressed or amplified in cancer. If a gene's protein product, a tumor marker, can be found elevated in the blood of diseased subjects then that tumor marker may be useful for cancer screening. Thus, with numerous gene discoveries come numerous candidate tumor markers. Translating a tumor marker discovery from the laboratory to use in a population requires stating a screening algorithm. The most commonly used algorithm, the single-threshold (ST) rule, classifies a subject positive (likely to have disease) when his or her marker concentration exceeds a common population-wide threshold. A better approach may be to use a longitudinal screening algorithm that makes use of a subject's accumulated Our screening rule uses parametric empirical Bayes (PEB) theory to generalize the ST rule to be conditional on screening history. Each subject's screening history is used to set an individually tailored threshold that achieves an arbitrary false-positive rate (FPR) . Controlling the FPR is particularly appropriate for cancer screening because costs (social and economic) are dominated by the rate of positive tests which, because disease prevalence is low in screening, is dominated by the error rate in the healthy subjects (FPR). Thus, an overarching constraint of any screening program is to limit the error rate in the healthy subjects, and any screening algorithm, whatever its detection rate or approach, must accommodate it.
With the PEB screening rule we find that a great majority of all subjects can have their cancer detected with marker concentration at levels far lower than with the ST rule, and so cancer is detected earlier. Importantly, this earlier detection is achieved while maintaining the same population FPR and so the overall cost of a screening program is controlled. The PEB rule uniformly dominates the ST rule, and can be used with any marker having some mathematical transformation that gives the healthy subjects a hierarchical normal marker distribution. These assumptions appear widely appropriate for many tumor markers (Crump et al., 2000; Pauler et al., 2001) . No specific restrictions are made on the behavior of the markers in the cases other than that their concentrations deviate (elevate or fall) from normal following cancer onset. Specimen requirements are modest, as serial measurements on cases are not needed.
Section 2 outlines the notation and statistical model assumed throughout the text. Section 3 uses the statistical model to derive the ST screening rule most commonly used in cancer screening, and then generalizes it to person-specific thresholds using PEB theory. All screening rules in Section 3 are defined to have comparable performance in healthy subjects, and the performance of the algorithm in diseased subjects is discussed by Section 4. Section 5 presents an example using CA 125 to screen for ovarian cancer. Section 6 provides a discussion of the robustness of our algorithm, and presents technical details that may be skipped. A summary is given in Section 7.
BACKGROUND AND NOTATION
We use Y j to represent the marker concentration at a person's jth screen, and D j to represent the disease status at that time; D j = 0 when disease free, and D j = 1 otherwise. We assume cancer does not regress, so D j = 1 implies D j = 1 for all j > j. We use lower case letters to denote observed quantities, and so the screening history from a subject having completed n screens is denoted y 1 , . . . , y n . Section 2.1 represents the statistical model used to represent the behavior of the marker when without cancer (when D j = 0), and Section 2.2 represents the behavior of the marker after cancer onset (when D j = 1). When without cancer our marker behaves in a manner similar to that used by Skates and Pauler (2001) , but whereas their method is for only a specific pre-clinical marker behavior, ours requires only that the marker deviates (elevates or falls) following cancer onset.
Marker behavior in subjects without cancer
We represent the marker concentration at the jth screen for a healthy subject with the following hierarchical model:
which implies that the marginal distribution of the marker in the population of healthy subjects is Note that the distributions above are implicitly conditioning on D j = 0. The individuals in a population are given person-specific normal marker levels denoted by µ (we suppress person-level subscripts for µ and Y j for clarity), but within subject variances, σ 2 , are assumed equal.μ and τ denote the mean and standard deviation of µ in the population, respectively.
Screening rules are invariant to monotonic transformation so generality is not lost by assuming distribution (3) for any continuous marker because then some transformation to normality is assured. Although our hierarchical model is similar to that used by other more complex methods (Slate and Cronin, 1997; Pauler et al., 2001; Skates and Singer, 1991) , the existence of suitable transformation for those methods is not assured because they require the transformation to be compatible with their specific marker growth model.
We can further reduce the total number of parameters in the model by re-centering and rescaling (both monotonic transformations) so that the marginal distribution (3) has zero mean and unit variance. This reduced model is given by
where
The reduced model (4)-(6) has only a single parameter, B 1 , which represents the fraction of total variability accounted for the between-woman variance. The reason for the subscript becomes apparent below. Because it has fewer parameters we will prefer it to the full model (1)-(3) when deriving our screening rules in Section 3. The model above and the screening rules below can be extended to accommodate fixed and time varying covariates (e.g. 'race' for the CA 125 ovarian cancer marker and 'age' for the prostate cancer marker PSA), and serial correlation. Time varying covariates and serial correlation must be accommodated if their effects are substantial in order to avoid bias. Including fixed covariates improves the overall precision of the screening rule. Accommodate fixed covariates by replacingμ with a linear predictor µ + Xβ (see Morris, 1983b and Pauler et al., 2001) . Accommodate time varying covariates by modeling the residuals, or deviations, from the population expected value. Specifically, if X t represents the covariate value at time t, andμ + X it β predicts the mean marker concentration for all subjects with covariate X t (i.e. age), then the residual R it = Y it − X it β follows the hierarchical model (1)-(3). Accommodate serial correlation by inflating (deflating) the within-person variance in (1) or (4) based on the time-dependence model used. For the remainder of this paper we assume that these effects have been accommodated so that the hierarchical model (4)- (6) is an adequate representation of the marker trajectory in healthy subjects.
Marker behavior with the onset of cancer
After cancer onset the level of a marker may deviate from its pre-cancer mean µ by an amount δ t , where t 0 represents the time since cancer onset. We assume 0 < δ t < δ t when t < t because most typically markers grow after cancer onset (see Baron et al., 1999 for a rare exception; our method is also appropriate for markers that descend after onset). Thus, when a subject has cancer the expected value of their marker is given by µ + δ t .
SCREENING RULES
The ST rule defines a single value and gives a positive screen to any subject found to have a marker that exceeds it. The threshold is chosen to achieve a specified population-wide FPR, denoted f 0 . Formally, the 
In contrast, a longitudinal algorithm determines a threshold that depends on the subject's screening history y 1 , . . . , y n . Formally, a positive screen is given to screen n + 1 if Y n+1 > c(y 1 , . . . , y n ; f 0 ), where the function c(y 1 , . . . , y n ; f 0 ) is determined by a particular choice of algorithm. This section shows how a longitudinal algorithm can be generated by naturally generalizing the ST rule while maintaining the overall FPR at f 0 = P(Y n+1 > c(y 1 , . . . , y n ; f 0 )|D n = 0, y 1 , . . . , y n ).
We generate screening rules using the logic of hypothesis tests (see McIntosh and Pepe, 2002 for the equivalence of hypothesis testing and screening test generation). All screening rules below use the reduced model (4)- (6) and assume that the model parametersμ, τ, σ and the transformation to marginal normality are known, or estimated with high precision. The actual number of specimens required to estimate the transformation and model parameters depends on the intended specificity of the screening algorithm; high specificity implies that the tail of the distribution must be accurate, and will increase data demands. However, because, serial samples are needed only on healthy subjects sufficient data can be accumulated in a short period of time. If needed, the models can be extended to allow for uncertainty in them (perhaps using a fully Bayesian framework, or with a mixed linear model and using best linear unbiased predictors).
Single-threshold screening rule
The ST rule is generated by the marginal distribution (6) by carrying out the hypothesis test
>μ with type I error rate equal to f 0 . The ST rule gives a positive screen whenever
An individually tailored screening rule
If µ were known perfectly the ST rule could be tailored to the individual by performing the hypothesis test
Because the between-subject source of variation is eliminated (equals B 1 in the reduced model) this limiting rule screens positive whenever
Intuitively we see that this limiting rule outperforms the ST rule because it detects deviations from normal that are √ 1 − B 1 × 100% the size but with the same FPR. We show this formally in Section 4.
A naïve sequential rule
Because µ is not known we must find a compromise rule than uses information about µ obtained over time. A subject undergoing an (n + 1)th screening event has a history of length n, and we summarize that history withȳ n = n j=1 y j /n. A simple approach to control for this history replaces µ in (7) withȳ n , but adjusts for the uncertainty inȳ n as an estimate of µ in order to maintain FPR = f 0 . In the reduced model this naïve sequential (NS) rule gives a positive screen whenever
Note that the NS rule has the same form as the ST and limiting rule but with the factor √ (1 − B 1 )(1 + 1/n). The ST rule (when n = 0) and the limiting rule (when n = ∞) are special cases of the NS rule. Intuitively we see that the NS rule can do better or worse than the ST rule depending on whether √ (1 − B 1 )(1 + 1/n) is less than or greater than unity, which is not assured when n or B 1 are small. For example, if B 1 = 1/4 then not until n = 5 will the naïve rule meet or exceed the performance of the ST rule. 
PEB screening rule
The NS rule replaces µ in (7) by its usual unbiased estimate,ȳ n . Here we propose replacing µ by its PEB estimate. PEB refers to the class of statistical procedures for estimating a group of individual means when drawn from a common population (for example see Morris, 1983b; Casella, 1985 and Efron and Morris, 1997 for technical and non-technical overviews of PEB methods). The PEB estimator, denotedμ n , is a function of the observed sample meanȳ n and the population parameters. The estimator is expressed aŝ
where the shrinkage factor B n equals (9) gives the PEB estimate for the reduced model. Although the expression (9) has the form of the familiar Bayes estimator we call it an empirical Bayes estimator because the 'prior' parameters are estimated empirically, and so the properties we attribute to it are frequentist in nature.
Because the shrinkage factor, B n , lies between zero (when n = 0) and one (when n is large) the PEB estimator is a compromise estimator that falls between the population mean and the individual's sample average. Because the shrinkage factor increases with n the PEB estimate comes into closer agreement with the individual average when history is plentiful. With small n the PEB estimator is closer to the population average. Thus, the PEB estimator allows the individual history to carry a greater voice when history is substantial, but anticipates regression for subjects having little screening history.
The PEB estimator has two properties that make it useful for screening:
(i) it is an unbiased estimate of a future observation just likeȳ n ,
In the reduced model we express this variance as
The expectations in (i) and (ii) are conditioned onȲ n =ȳ n and the population parameters. See Morris (1983a) for derivations, but note that the definition of B 1 and B n used here differs slightly. When no covariates are used these properties may be derived using normal regression formulae as well. For example, derive property (i) by noting Cov(Y n+1 ,Ȳ n ) = τ 2 and Var(Y n ) = τ 2 + σ 2 /n, and so regressing Y n+1 onȲ n gives the coefficient τ 2 /(τ 2 + σ 2 /n) = B n . The advantage of the PEB viewpoint over the regression viewpoint is that generalization to covariates is straightforward. We generalize the ST rule with the PEB estimator using the hypothesis test
μ n , and reject when Y n+1 exceeds its conditional expectation by too much. The distribution of Y n+1 −μ n under the null is normal, with variance given by
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. Thus, the PEB rule gives Y n+1 a positive screen whenever
Note that when no history is available the PEB rule has B n = B 0 = 0, and the PEB rule equals the ST rule. Subjects with long screening history have B ∞ = 1 and the PEB rule equals the limiting rule (7). Between these extremes the PEB rule provides a smooth generalization of these rules. A specific example of the PEB rule is given in Section 5. The derivations above assume the population parameters are estimated with high precision. If the model parameters are estimated with substantial error then (11) must be adjusted to reflect this added uncertainty. Perhaps the simplest approach would be to add additional terms to (11) to inflate the variance until data become more abundant (for example see Section 5 of Morris, 1983b) .
PERFORMANCE OF SCREENING RULES IN CANCER CASES
This section investigates the behavior of the PEB rule in diseased subjects by providing expressions for its sensitivity, or true positive rate (TPR). The exact TPR of any particular screening rule depends on how soon after cancer onset the screen takes place, and on aspects of the tumor's growth behavior which are not known. The TPR of the NS and PEB rules depend also on the abundance of screening history at the time of the screen. Because we wish to avoid stating a growth model we expresses the TPR of each rule when the marker has elevated a fixed but arbitrary amount δ > 0; that is, the marker Y n+1 now has an expectation equal to µ + δ instead of µ, but has the same variance.
With screening history summarized byȳ n and cancer onset occurring after the nth screen, the PEB screening rule with n historical screens is expressed as
and from expression (11) this becomes
where Z represents a standard normal distribution, z 1− f 0 its upper 1 − f 0 quantile. Moreover, by choosing n = 0 or n = ∞ expression (13) represents the TPR of the ST and limiting rules, respectively. Because t 0 t n t ∞ the PEB always outperforms the ST rule and will eventually meet, but never exceed, the performance of the limiting rule. The PEB rule always outperforms the NS rule too because
The PEB TPR (13) is computed assuming that the cancer onset occurs following the nth screen, which assures that screening history is uncontaminated with any false negative measurements. False negatives must be addressed because a marker that elevates but not enough to cause a positive screen will cause (12) to deviate from optimal on subsequent screens. It is not immediately apparent that the PEB rule should still be preferred to the ST rule in the presence of false negatives. Section 6 shows that individuals and the population should prefer the PEB rule to the ST rule even with the risk of a false negative. We first give an example of the PEB rule using the CA 125 ovarian cancer tumor marker. Most women diagnosed with ovarian cancer are diagnosed at a late stage, and nearly all die from their disease. However, most of those few diagnosed with early stage disease survive. This suggests that early detection of ovarian cancer may have a dramatic impact on mortality. Because the disease is relatively rare, it is difficult to obtain serial specimens collected during the suspected pre-clinical period. However, many longitudinal cohort studies have very large stores of serum for asymptomatic women that can be used to estimate the PEB algorithm. For example, a ten year study of over 1200 high-risk women (Karlan et al., 1993) was used by Crump et al. (2000) to determine the information sufficient to implement the PEB algorithm for five different ovarian cancer tumor markers. Here we present the algorithm for the CA 125 tumor marker.
Implementing the algorithm
Many studies report that log(CA 125) in healthy subjects has a normal distribution, with B 1 falling between 0.6 in a high-risk population (Crump et al., 2000) and 0.9 in a general-risk population ). The population mean log(CA 125) level,μ, has been found to depend on the type of CA 125 assay used (Davelaar et al., 1988) , and the menopausal status and race of the women (Crump et al., 2000; Karlan et al., 1993; Pauler et al., 2001) . However, the value of B 1 is unaffected by these covariates (e.g. pre-and post-menopausal women appear to have the same B 1 even though they have differentμ; Crump et al., 2000) .
The PEB screening algorithm presented here uses a FPR f 0 = 0.01, and B 1 = 0.6, the lowest reported value B 1 for log(CA 125). Higher values of B 1 will imply better performance of the PEB rule compared to the ST rule. For convenience the mean and marginal variance of log(CA 125) are selected asμ = log(10) and √ σ 2 + τ 2 = 0.5, respectively. This mean is similar to that observed for a population of post-menopausal women (Crump et al., 2000) , and a different mean should be used if applied to a premenopausal population. Because serial correlation between subsequent log(CA 125) values cannot be detected when observed more than one month apart (Crump et al., 2000) , we may safely ignore serial correlation in our model for any screening program with intervals exceeding that amount of time.
For a fixed amount of history, n, the PEB rule (12) is linear inȳ n , with slope equaling B n , and so it can be displayed graphically, as in Figure 1a . The horizontal axis represents the mean of a woman's historical log(CA 125) levels, and each line in the figure is labeled by n, the number of screens used to compute the mean. The line with label n = 0 represents the ST rule and has intercept z 1− f 0 = z 0.99 = 2.33, and slope B 0 = 0. Subsequent screens have slopes B n that increase to B ∞ = 1, and an intercept that reduces to 2.33 √ 1 − B 1 . We can transform back to the raw CA 125 scale too, as in Figure 1b , whose horizontal line gives a CA 125 threshold of exp μ + z 1− f 0 × √ σ 2 + τ 2 = exp(log(10) + 2.33 × 0.50) = 32. Figure 1a shows that the PEB rule diverges from the ST rule as history accumulates. The few women who have naturally high CA 125 concentrations will have thresholds above the ST rule, but the majority will have lower thresholds, some dramatically so. Because an average healthy woman hasȳ n = 0 (reduced model), we see that far more than half of all women will have a lower threshold if using the PEB rule. Indeed, average women have a ST rule threshold of 2.33, but this becomes 80% of it (or 20% smaller) after only a single screen, √ 1 − 0.6 2 = 1.86, and only 20% (or 80% smaller) of it after several screens, √ 1 − 0.6 = 1.47. Figure 1a shows that all women having histories withȳ n less than approximatelyȳ n = 1 are given lower thresholds. The exact fraction with a lower threshold is given by P(Ȳ n < 1) which depends on the specific value of B 1 and n; larger values of either increase the fraction with lowered thresholds. For our example 84, 88, 89, and 95% of women are given lower thresholds for n = 1, 2, 3, ∞, respectively. Thus, when using the PEB rule the overwhelming majority of women will have a lower threshold than the ST rule gives them, and so their cancers can be detected earlier. A key point is that the PEB rule gives this lower threshold while maintaining the same population-wide FPR. Of course, lowering the threshold will increase an individual's FPR compared with the ST rule. In order to maintain the population-wide error rate the increase experienced by the majority must be offset by a concomitant decrease found by the minority. The fact that increasing the threshold in a small fraction of women permits drastic reductions in the thresholds of the majority is a consequence of the fact that when markers behave heterogeneously the ST thresholds are determined by a few extreme cases. Indeed, in our example 5% of women experience over half the false positives when the ST rule is used. The PEB rule spreads the burden of false positives evenly throughout the population so that all women have the same burden, or better, it can even permit each woman to choose her own FPR, depending on her own screening history. A consequence is a dramatic increase in the cancer detection ability, as we see next.
The behavior in cases
The TPR of the PEB rule to detect an elevation δ > 0 is given by t n , in (13). The practical significance of any elevation must be made on a case-by-case basis. For demonstration purposes only we choose δ = 1 as a convenient and arbitrary marker elevation of one marginal standard error. The solid curves in Figure 2 relate the TPR (vertical axis) versus FPR (horizontal axis) over a low range of FPR relevant for screening (i.e. low FPRs). Such curves are often referred to as receiver-operating characteristic (ROC) curves and may be used to characterize the performance of diagnostic tests (Hanley and McNeil, 1982) . Each plot represents the ROC curve with different values of n.
When no history is available (Figure 2 ) the PEB and ST rules detect 26% of the cases at f 0 = 0.05. When only a single historic screen is available nearly 34% of such cases can be detected by the PEB rule, and with one additional screen the PEB rule finds 38% of them. With substantial history (n = ∞) the PEB rule finds 47% of cases, which represents a relative 77% improvement over the ST rule. With f 0 = 0.01 these percentages are 10, 15, 17, and 23, respectively. The gain in performance will be greater for larger values of B 1 , but for any fixed elevation, and any B 1 > 0, the PEB ROC curves will uniformly dominate the ST rules. Note that for even this modest B 1 , controlling for only a single historical screen (n = 1) achieves a 30% increase in TPR, which is nearly half the potentially achievable amount. This suggests that only a few recent screens need to be controlled for in order to obtain the majority of benefit of the PEB rule. Screens in the distant past may be ignored without substantial loss of performance.
The performance in a population
A comprehensive ovarian cancer microsimulation model has been used to evaluate the behavior of the PEB algorithm in a large cohort of women in the US Urban et al., 2002) . The microsimulation model, explained in detail by Urban et al. (1997 Urban et al. ( , 1998 , is intended to examine the cost and health impact of ovarian cancer screening programs. These simulations are quite comprehensive. The life histories (cancer incidence, cancer death, treatment, and other cause death) for the US population are modeled to reflect US Census Bureau life tables and the age-adjusted US cancer incidence. Urban et al. (2002) used the microsimulation model and the PEB algorithm to estimate the performance of screening expected when using a screening protocol similar to that outlined by Skates and Singer (1991) , who recommend two levels of positivity for a screen: positive screen for extreme elevations and early recall for modest ones. Note that for ovarian cancer a positive screen from a marker results in referral to ultrasound, not surgery. The PEB algorithm used a FPR of 2% to define the extreme, and 15% for modest (i.e. 13% of healthy women were recalled early). With annual screening this configuration of the PEB algorithm detects 70% of cancers before their clinical diagnosis, whereas the ST rule finds only 46% of them. Importantly, the PEB rule finds over 50% when at early stage compared with a mere 30% by the ST rule, and only 20% without screening. The PEB rule found an expected 31% drop in cause specific mortality compared with the 18% of the ST rule. This simulation study used B 1 = 0.6, which is lower than what is now reported in general-risk populations with a modern assay Pauler et al., 2001) using higher values of B 1 would find even greater improvement.
The predictions of Urban et al. (2002) are very close to that of the complex algorithm described by Skates and Pauler (2001) : they predict 60% of cancers detected at early stage. These simulations are not exactly comparable because Skates and Pauler (2001) Urban et al. (2002) if these more favourable assumptions were made.
ROBUSTNESS OF THE PEB RULE TO FALSE NEGATIVES AND THE TUMOR GROWTH MODEL
Following a false negative the PEB threshold will be slightly too high because, although an elevation was not dramatic enough to cause a positive screen, on average false negative screens will be biased upward. Here we summarize formal, informal, and simulation evidence to argue that contamination is not a problem sufficient enough to prevent the strong preference of the PEB rule over the ST rule even for subjects who experience a false negative.
On a population level the PEB rule can be said to be superior to the ST rule if subjects can be expected, on average, to have a better outcome under the PEB rule than the ST rule. This is the criterion used by Skates and Pauler (2001) to determine the superiority of their algorithms. The simulation studies of Urban et al. (2002) , summarized in Section 5.3, showed that the PEB rule dominates the ST rule in all outcome categories when using CA 125 to screen for ovarian cancer. used the same model to show that the dominance holds for a wide variety of other markers by varying the range of B 1 between 0.1 and 0.9. Importantly, of the over 15 000 cancer cases simulated by not a single subject was diagnosed later using the PEB rule than using the ST rule, even though false negative screens occurred frequently. This suggests that the PEB rule dominance may extend beyond the population level to the individual level. We may use the simple framework of the PEB rule to investigate this more formally. Consider a subject whose initial screen is falsely negative, and is elevated by δ 1 , second screen by δ 2 , etc. The (n + 1)th screen is elevated by δ n+1 and the PEB threshold is biased upward byδ n B n wherē δ n = n j=1 δ n /n. Any marker growth model where the difference δ n+1 −δ n B n increases with time assures that the detection rate of the PEB algorithm will not degrade following a false negative because the increase in the marker growth outruns the bias in the PEB estimate. A convex growth model (e.g. linear growth) on the transformed scale is sufficient for this, but not necessary. If not all the historical screens are false negative then the effect of a false negative is dampened, with the upward bias equaling c nδ c B n , where c n represents the number of n screens that are false negatives.
We can make even more precise statements if we assume a linear growth model with rate β per screening interval. The upward bias in the threshold is then less than c n βc 2 B n , and so a true elevation of β(c + 1) appears to the PEB rule as being too small due to contamination by a factor 1 − and when it holds a very strong statement can be made: the PEB rule has higher detection than the ST rule following c false negatives. For example, for subjects whose only screen was false negative (n = 1, c = 1) then any B 1 > 17/32 satisfies the inequality. Far lower B 1 are sufficient if the history contained only a single true negative result. Note that the expression above is independent of the growth parameter β, and so a linear or greater growth model, on the transformed scale, whatever the parameter or growth shape, is sufficient for the PEB rule to dominate the ST rule. This is in contrast to the complex change point models which rely on a specific growth curve and parameters in order to claim optimal performance. It is unclear how those algorithms will perform with models or parameters different from those assumed.
These conclusions are stronger than the population-based ones demonstrated by the microsimulation models: even if the inequality does not hold the population can still find greater performance because the degradation following a false negative can be offset by the lower probability of having one in the first place. However, the inequality above does show that the only subjects at risk of later detection with a sequential rule are those who experience a false negative at the start of the screening program. If B 1 is very small and early false negatives are thought to be common, then diligence may be used early on, but after only a few screens, the PEB rule dominates the ST rule for even that critical sub-population.
SUMMARY AND CONCLUSIONS
Our approach uses PEB methods to control for screening history and give each subject a pre-specified FPR at every screen. Although the PEB rule can maintain the same population-wide FPR as the ST rule, the great majority of subjects will have lower thresholds, and so their cancers can be detected earlier.
The PEB algorithm works best, compared with the ST rule, with markers that have high population heterogeneity. The PEB rule has an advantage over other complex methods because by comparison it has modest data needs, and does not depend on a specific growth model.
The PEB algorithm may be particularly useful when natural history is not well known, but it is important to consider what may be lost by using it instead of algorithms like that of Skates and Pauler (2001) when the pre-clinical model is well known. Complex algorithms may have particular advantages when differential screening intervals are used. This is due to their explicit representation of time in their approach. For example, Skates and Pauler treat a marker elevation as more significant if it occurs over a shorter time interval, whereas the PEB method considers only the magnitude of the elevation. Although this may not be important in a screening program with a fixed screening interval, it may be so with screening protocols similar to that recommended by Skates and Pauler (2001) , who schedule the screening interval based on observed marker changes.
As appealing as accommodating time is, doing so apparently requires stating a complex change point model which, as we have argued, is difficult to estimate. When their model is correct, theory suggests that the Skates and Pauler approach will perform better than the PEB method, but the simulation results summarized in Section 5.3 (which use differential recall rates comparable to Skates and Pauler) suggest that the gain may be only small, at least for ovarian cancer and CA 125. It is also unclear how much a complex algorithm will degrade with model misspecification. At this time no general statement can be made about the relative performance of the PEB method and the more complex methods.
Several modifications to the PEB rule may be considered to make them even more robust and widely applicable. For example, the PEB rules above use the complete screening history. However, screening takes place over several years, or decades, and subjects will accumulate an extraordinary screening history in their lifetimes. Because most of the gain from longitudinal screening can come with only a few historical screens, depending on the value of B 1 (see Section 5), a practical adaptation of the PEB method is to omit the distant past. This will result in little degradation of screening performance but will decrease model dependence.
The PEB method assumes that the markers in the healthy subjects can, with some transformation, be represented in a hierarchical normal model. The existence of a transformation to marginal normality is automatic for any marker measured on a continuous scale. Only the addition of the within-subject normality, with equal variance, must be accommodated within the parametric structure. If that assumption appears to fail, the PEB methods presented here can be extended, almost without modification, to a wider class of continuous and discrete distributions, including the Gamma, Poisson, and binomial families (Morris, 1982 (Morris, , 1983a . The assumptions of the general PEB approach are probably appropriate for a large number of tumor markers, and assist timely translation of tumor marker discoveries.
